Jones Financial Companies Lllp Has $578,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $973.13
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average rating of “Moderate Buy” from the ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Morningstar13d
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Nasdaq16d
Regeneron Pharmaceuticals Reports Positive Results for Investigational Gene Therapy DB-OTO in Children with Otoferlin-Related Hearing Loss
In the initial dose-escalation cohort (Part A), participants receive a single intracochlear injection ... applications of products marketed or otherwise commercialized by Regeneron and/or its ...
Morningstar4d
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
It’s an injection given under the skin (subcutaneous ... and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Mena FN22d
Dupixent® (Dupilumab) Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid (BP)
It's an injection given under the skin (subcutaneous injection ... commercialized by Regeneron and/or its collaborators or licensees (collectively,“Regeneron's Products”) and product candidates being ...